Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Bevacizumab
100%
Hepatocellular Cancer
100%
Transarterial Chemoembolization
100%
Vascular Endothelial Growth Factor
18%
O-arm
18%
Neovessel
13%
Angiography
9%
Progression-free Survival
9%
Pharmacokinetics
4%
Factor Level
4%
Monoclonal Antibody
4%
Progressive Disease
4%
Median Overall Survival
4%
Overall Survival
4%
Neovascularization
4%
Tumor Regrowth
4%
Trial Registration
4%
Life-threatening
4%
Historical Controls
4%
Medicine and Dentistry
Malignant Neoplasm
100%
Bevacizumab
100%
Transcatheter Arterial Chemoembolization
100%
Arm
36%
Vasculotropin
18%
Angiography
13%
Overall Survival
9%
Progression Free Survival
9%
Neoplasm
4%
Monoclonal Antibody
4%
Progressive Disease
4%
Minoxidil
4%
Pharmacokinetic
4%
Pharmacology, Toxicology and Pharmaceutical Science
Malignant Neoplasm
100%
Bevacizumab
100%
Vasculotropin
36%
Overall Survival
18%
Progression Free Survival
18%
Pharmacokinetic
9%
Diseases
9%
Neoplasm
9%
Monoclonal Antibody
9%
Minoxidil
9%
Immunology and Microbiology
Bevacizumab
100%
Arm
72%
Vasculotropin
36%
Overall Survival
18%
Progression Free Survival
18%
Monoclonal Antibody
9%
Pharmacokinetic
9%
Neuroscience
Bevacizumab
100%
Vascular Endothelial Growth Factor
36%
Angiography
27%
Monoclonal Antibody
9%
Minoxidil
9%
Pharmacokinetic
9%